Health Care

Health Care Equipment

20 companies under coverage.

Coverage

Health Care Equipment

Stryker Corporation (SYK)

HOLD. 12-month probability-weighted target $314 (+14% vs spot). P/E Multiple explains 69% of Monte Carlo outcome variance.

SYKEquity ResearchMonte Carlo

9 September 2026Rating: HOLD · +3.6%

Equity Research

Intuitive Surgical Inc (ISRG)

HOLD. 12-month probability-weighted target $404 (+15% vs spot). P/E Multiple explains 81% of Monte Carlo outcome variance.

ISRGEquity ResearchMonte Carlo

9 September 2026Rating: HOLD · +0.6%

Equity Research

Globus Medical (GMED)

HOLD. 12-month probability-weighted target $76 (+1% vs spot). P/E Multiple explains 64% of Monte Carlo outcome variance.

GMEDEquity ResearchMonte Carlo

9 September 2026Rating: HOLD · -0.3%

Equity Research

Edwards Lifesciences Corp (EW)

HOLD. 12-month probability-weighted target $88 (+1% vs spot). P/E Multiple explains 75% of Monte Carlo outcome variance.

EWEquity ResearchMonte Carlo

9 September 2026Rating: HOLD · -3.1%

Equity Research

LivaNova PLC (LIVN)

HOLD. 12-month probability-weighted target $79 (-2% vs spot). P/E Multiple explains 55% of Monte Carlo outcome variance.

LIVNEquity ResearchMonte Carlo

9 September 2026Rating: HOLD · -4.2%

Equity Research

Insulet Corporation (PODD)

HOLD. 12-month probability-weighted target $151 (+6% vs spot). P/E Multiple explains 52% of Monte Carlo outcome variance.

PODDEquity ResearchMonte Carlo

9 September 2026Rating: HOLD · -4.9%

Equity Research

IDEXX Laboratories Inc (IDXX)

HOLD. 12-month probability-weighted target $542 (+4% vs spot). P/E Multiple explains 75% of Monte Carlo outcome variance.

IDXXEquity ResearchMonte Carlo

9 September 2026Rating: HOLD · -5.2%

Equity Research

Boston Scientific Corp (BSX)

HOLD. 12-month probability-weighted target $44 (-3% vs spot). P/E Multiple explains 71% of Monte Carlo outcome variance.

BSXEquity ResearchMonte Carlo

9 September 2026Rating: HOLD · -8.7%

Equity Research

STERIS plc (STE)

HOLD. 12-month probability-weighted target $210 (-4% vs spot). P/E Multiple explains 60% of Monte Carlo outcome variance.

STEEquity ResearchMonte Carlo

9 September 2026Rating: HOLD · -10.6%

Equity Research

ResMed Inc (RMD)

SELL. 12-month probability-weighted target $201 (-9% vs spot). P/E Multiple explains 78% of Monte Carlo outcome variance.

RMDEquity ResearchMonte Carlo

9 September 2026Rating: SELL · -10.9%

Equity Research

Bruker Corporation (BRKR)

HOLD. 12-month probability-weighted target $55 (-5% vs spot). P/E Multiple explains 57% of Monte Carlo outcome variance.

BRKREquity ResearchMonte Carlo

9 September 2026Rating: HOLD · -13.5%

Equity Research

Medtronic PLC (MDT)

HOLD. 12-month probability-weighted target $86 (-7% vs spot). P/E Multiple explains 66% of Monte Carlo outcome variance.

MDTEquity ResearchMonte Carlo

9 September 2026Rating: HOLD · -18.7%

Equity Research

Zimmer Biomet Holdings Inc (ZBH)

HOLD. 12-month probability-weighted target $90 (-4% vs spot). P/E Multiple explains 63% of Monte Carlo outcome variance.

ZBHEquity ResearchMonte Carlo

9 September 2026Rating: HOLD · -18.9%

Equity Research

GE HealthCare Technologies Inc. (GEHC)

HOLD. 12-month probability-weighted target $63 (-5% vs spot). Gross Margin explains 62% of Monte Carlo outcome variance.

GEHCEquity ResearchMonte Carlo

9 September 2026Rating: HOLD · -19.2%

Equity Research

Baxter International Inc (BAX)

SELL. 12-month probability-weighted target $20 (-18% vs spot). Gross Margin explains 67% of Monte Carlo outcome variance.

BAXEquity ResearchMonte Carlo

9 September 2026Rating: SELL · -21.2%

Equity Research

Abbott Laboratories (ABT)

SELL. 12-month probability-weighted target $93 (-12% vs spot). P/E Multiple explains 66% of Monte Carlo outcome variance.

ABTEquity ResearchMonte Carlo

9 September 2026Rating: SELL · -22.2%

Equity Research

Revvity Inc. (RVTY)

SELL. 12-month probability-weighted target $108 (-15% vs spot). P/E Multiple explains 65% of Monte Carlo outcome variance.

RVTYEquity ResearchMonte Carlo

9 September 2026Rating: SELL · -24.2%

Equity Research

DexCom Inc (DXCM)

SELL. 12-month probability-weighted target $65 (-23% vs spot). P/E Multiple explains 64% of Monte Carlo outcome variance.

DXCMEquity ResearchMonte Carlo

9 September 2026Rating: SELL · -27.3%

Equity Research

Becton Dickinson and Company (BDX)

SELL. 12-month probability-weighted target $147 (-18% vs spot). P/E Multiple explains 56% of Monte Carlo outcome variance.

BDXEquity ResearchMonte Carlo

9 September 2026Rating: SELL · -30.7%

Equity Research

Penumbra Inc (PEN)

SELL. 12-month probability-weighted target $202 (-37% vs spot). Gross Margin explains 50% of Monte Carlo outcome variance.

PENEquity ResearchMonte Carlo

9 September 2026Rating: SELL · -45.5%